133 related articles for article (PubMed ID: 38349262)
21. A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme.
Nehoff H; Parayath NN; McConnell MJ; Taurin S; Greish K
Oncotarget; 2015 Nov; 6(35):37948-64. PubMed ID: 26517812
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of novel caffeic acid phenethyl ester (CAPE) derivatives and their biological activity studies in glioblastoma multiforme (GBM) cancer cell lines.
Sucu BO; Koc EB; Savlug Ipek O; Mirat A; Almas F; Guzel MA; Dogan B; Uludag D; Karakas N; Durdagi S; Guzel M
J Mol Graph Model; 2022 Jun; 113():108160. PubMed ID: 35248814
[TBL] [Abstract][Full Text] [Related]
23. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
24. MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme.
Sufit A; Lee-Sherick AB; DeRyckere D; Rupji M; Dwivedi B; Varella-Garcia M; Pierce AM; Kowalski J; Wang X; Frye SV; Earp HS; Keating AK; Graham DK
PLoS One; 2016; 11(10):e0165107. PubMed ID: 27783662
[TBL] [Abstract][Full Text] [Related]
25. Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery.
Brar HK; Jose J; Wu Z; Sharma M
Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678688
[TBL] [Abstract][Full Text] [Related]
26. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Raizer JJ
J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
[TBL] [Abstract][Full Text] [Related]
27. Tumor protease-activated theranostic nanoparticles for MRI-guided glioblastoma therapy.
Huang CH; Chang E; Zheng L; Raj JGJ; Wu W; Pisani LJ; Daldrup-Link HE
Theranostics; 2023; 13(6):1745-1758. PubMed ID: 37064879
[No Abstract] [Full Text] [Related]
28. SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment.
Ceccherini E; Indovina P; Zamperini C; Dreassi E; Casini N; Cutaia O; Forte IM; Pentimalli F; Esposito L; Polito MS; Schenone S; Botta M; Giordano A
J Cell Biochem; 2015 May; 116(5):856-63. PubMed ID: 25521525
[TBL] [Abstract][Full Text] [Related]
29. Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide.
Sukumar UK; Bose RJC; Malhotra M; Babikir HA; Afjei R; Robinson E; Zeng Y; Chang E; Habte F; Sinclair R; Gambhir SS; Massoud TF; Paulmurugan R
Biomaterials; 2019 Oct; 218():119342. PubMed ID: 31326657
[TBL] [Abstract][Full Text] [Related]
30. MP-Pt(IV): A MAOB-Sensitive Mitochondrial-Specific Prodrug for Treating Glioblastoma.
Raghavan S; Baskin DS; Sharpe MA
Mol Cancer Ther; 2020 Dec; 19(12):2445-2453. PubMed ID: 33033175
[TBL] [Abstract][Full Text] [Related]
31. Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma.
Zhang L; Yang Z; Sang H; Jiang Y; Zhou M; Huang C; Huang C; Wu X; Zhang T; Zhang X; Wan S; Zhang J
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1541-1552. PubMed ID: 34238111
[TBL] [Abstract][Full Text] [Related]
32. Recent advancements and theranostics strategies in glioblastoma therapy.
Baddam SR; Kalagara S; Kuna K; Enaganti S
Biomed Mater; 2023 Aug; 18(5):. PubMed ID: 37582381
[TBL] [Abstract][Full Text] [Related]
33. AuNP Pyrazolo[3,4-
Molinari A; Iovenitti G; Mancini A; Gravina GL; Chebbi M; Caruana M; Vignaroli G; Orofino F; Rango E; Angelucci A; Dreassi E; Schenone S; Botta M
ACS Med Chem Lett; 2020 May; 11(5):664-670. PubMed ID: 32435368
[TBL] [Abstract][Full Text] [Related]
34. Magnetic targeting of paclitaxel-loaded poly(lactic-
Ganipineni LP; Ucakar B; Joudiou N; Bianco J; Danhier P; Zhao M; Bastiancich C; Gallez B; Danhier F; Préat V
Int J Nanomedicine; 2018; 13():4509-4521. PubMed ID: 30127603
[TBL] [Abstract][Full Text] [Related]
35. Harnessing nanomedicine for therapeutic intervention in glioblastoma.
Gutkin A; Cohen ZR; Peer D
Expert Opin Drug Deliv; 2016 Nov; 13(11):1573-1582. PubMed ID: 27292970
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.
Okuda T; Tasaki T; Nakata S; Yamashita K; Yoshioka H; Izumoto S; Kato A; Fujita M
Anticancer Res; 2017 Jul; 37(7):3871-3876. PubMed ID: 28668888
[TBL] [Abstract][Full Text] [Related]
37. The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.
Jensen KV; Cseh O; Aman A; Weiss S; Luchman HA
PLoS One; 2017; 12(12):e0189670. PubMed ID: 29253028
[TBL] [Abstract][Full Text] [Related]
38. Non-invasive transferrin targeted nanovesicles sensitize resistant glioblastoma multiforme tumors and improve survival in orthotopic mouse models.
Sandbhor P; Goda J; Mohanty B; Chaudhari P; Dutt S; Banerjee R
Nanoscale; 2021 Dec; 14(1):108-126. PubMed ID: 34897360
[TBL] [Abstract][Full Text] [Related]
39. Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors.
Yuan J; Zhang F; Hallahan D; Zhang Z; He L; Wu LG; You M; Yang Q
J Exp Clin Cancer Res; 2018 Aug; 37(1):181. PubMed ID: 30071868
[TBL] [Abstract][Full Text] [Related]
40. Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.
Dai L; Zhou P; Lyu L; Jiang S
BMC Cancer; 2023 Dec; 23(1):1249. PubMed ID: 38114959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
